



## Joint Working Executive Summary

Published on [www.bayer.co.uk](http://www.bayer.co.uk)

<b>Project title</b>	Redesign of Macular Service at Taunton & Somerset NHS Foundation Trust
<b>Project partners</b>	Taunton & Somerset Hospital NHS Foundation Trust Bayer plc
<b>Project summary</b>	<p>The ophthalmology department at Taunton Hospital, part of Taunton &amp; Somerset Hospital NHS Foundation Trust, is facing a number of issues with capacity to deliver its services therefore a service redesign is being proposed to address these capacity issues.</p> <p>The project will involve:</p> <ul style="list-style-type: none"><li>• Training for appropriate HCPs in the use of new imaging technology, and to give treatment to patients according to agreed pathways</li><li>• Implementation of new technology to allow improvements in the management of specific patient groups</li><li>• Implementation of recognised quality improvement methodologies to continuously develop and improve services to optimise outcomes for patients</li><li>• Initiation of virtual clinics for medical retinal patients, as well as for patients referred from the diabetic screening service and additional macular treatment</li></ul> <p>These changes will be implemented by the redesign of patient pathways and embedded via the use of improvement methodologies.</p>
<b>Expected benefits to patients, the NHS and Bayer</b>	<p><b>Benefits for Patients:</b></p> <ul style="list-style-type: none"><li>• Timely and convenient access to treatment following diagnosis</li><li>• Better patient experience in streamlined Reverse Virtual Anti-VEGF clinics</li><li>• The potential to improve outcomes by being treated according to national guidelines</li><li>• Access to additional diagnostic equipment and improved clinical pathways at the local hospital will mean fewer out of area referrals and therefore facilitate more care closer to home for patients</li></ul> <p><b>Benefits for the NHS:</b></p> <ul style="list-style-type: none"><li>• Virtual review of patient referrals from Regional and National Screening Programmes will reduce waiting times for these patients and enable rapid diagnosis and appropriate treatment according to national guidelines.</li><li>• Workforce redesign in conjunction with pathway redesign will allow the Trust to manage resources effectively to optimise patient outcomes</li><li>• The addition of new technology will reduce the number of out of area referrals</li></ul>

	<b>Benefits for Bayer:</b> <ul style="list-style-type: none"><li>• Improved reputation by demonstrating commitment and willingness to invest in improving patient care through a fully transparent Joint Working Agreement with Taunton &amp; Somerset</li><li>• Improving NICE-approved medicines optimisation of injectable therapies, of which Bayer's aflibercept is one, in line with national guidelines due to improving capacity for provision</li><li>• Better understanding of Taunton &amp; Somerset and patients' needs</li></ul>
<b>Start date</b>	October 2017

Date of Preparation: October 2017

Job bag number: UKEYL03170074c